These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 2317223)
1. Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations. Degiannis D; Seibold JR; Czarnecki M; Raskova J; Raska K Arthritis Rheum; 1990 Mar; 33(3):375-80. PubMed ID: 2317223 [TBL] [Abstract][Full Text] [Related]
2. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis. Lee YJ; Shin KC; Kang SW; Lee EB; Kim HA; Song YW Clin Exp Rheumatol; 2001; 19(1):69-74. PubMed ID: 11247328 [TBL] [Abstract][Full Text] [Related]
3. Soluble serum interleukin 2 receptors in patients with systemic sclerosis. Steen VD; Engel EE; Charley MR; Medsger TA J Rheumatol; 1996 Apr; 23(4):646-9. PubMed ID: 8730120 [TBL] [Abstract][Full Text] [Related]
4. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. Polisson RP; Gilkeson GS; Pyun EH; Pisetsky DS; Smith EA; Simon LS J Rheumatol; 1996 Apr; 23(4):654-8. PubMed ID: 8730122 [TBL] [Abstract][Full Text] [Related]
5. [Soluble receptors of cytokines in sera of patients with systemic sclerosis--clinical correlation]. Lis AD; Brzezińska-Wcisło LA Wiad Lek; 2003; 56(11-12):532-6. PubMed ID: 15058159 [TBL] [Abstract][Full Text] [Related]
6. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis. Majewski S; Wojas-Pelc A; Malejczyk M; Szymanska E; Jablonska S Acta Derm Venereol; 1999 May; 79(3):207-10. PubMed ID: 10384918 [TBL] [Abstract][Full Text] [Related]
7. Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin. Søndergaard K; Stengaard-Pedersen K; Zachariae H; Heickendorff L; Deleuran M; Deleuran B Br J Rheumatol; 1998 Mar; 37(3):304-10. PubMed ID: 9566672 [TBL] [Abstract][Full Text] [Related]
8. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma. Ihn H; Sato S; Fujimoto M; Kikuchi K; Takehara K Br J Dermatol; 1996 May; 134(5):843-7. PubMed ID: 8736323 [TBL] [Abstract][Full Text] [Related]
9. Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Kiener H; Graninger W; Machold K; Aringer M; Graninger WB Clin Exp Rheumatol; 1994; 12(5):483-7. PubMed ID: 7842528 [TBL] [Abstract][Full Text] [Related]
11. Pentoxyfilline treatment does not influence the plasma levels of IL-2 and sIL-2R in limited scleroderma patients. Chibowska M; Krasowska D; Weglarz J Med Sci Monit; 2001; 7(2):282-8. PubMed ID: 11257736 [TBL] [Abstract][Full Text] [Related]
12. Circulating interleukin 1 beta and soluble interleukin 2 receptor: evaluation as markers of disease activity in scleroderma. Patrick MR; Kirkham BW; Graham M; Harrision LC J Rheumatol; 1995 Apr; 22(4):654-8. PubMed ID: 7791158 [TBL] [Abstract][Full Text] [Related]
13. Long-term therapy with plasma exchange in systemic sclerosis: effects on laboratory markers reflecting disease activity. Cozzi F; Marson P; Rosada M; De Silvestro G; Bullo A; Punzi L; Todesco S Transfus Apher Sci; 2001 Aug; 25(1):25-31. PubMed ID: 11791759 [TBL] [Abstract][Full Text] [Related]
14. Elevation of soluble interleukin-2 receptor levels in the bronchoalveolar lavage from patients with systemic sclerosis. Martinez JA; Nishimura C; Guatura SB; Sato E; King TE Rheumatol Int; 2001 Nov; 21(3):122-6. PubMed ID: 11765225 [TBL] [Abstract][Full Text] [Related]
15. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Hasegawa M; Sato S; Ihn H; Takehara K Rheumatology (Oxford); 1999 Jul; 38(7):612-7. PubMed ID: 10461473 [TBL] [Abstract][Full Text] [Related]
16. Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis. Famularo G; Procopio A; Giacomelli R; Danese C; Sacchetti S; Perego MA; Santoni A; Tonietti G Clin Exp Immunol; 1990 Sep; 81(3):368-72. PubMed ID: 2397608 [TBL] [Abstract][Full Text] [Related]
17. Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis. Klimiuk PA; Sierakowski S; Latosiewicz R; Cylwik JP; Cylwik B; Skowronski J; Chwiecko J Clin Exp Rheumatol; 2003; 21(1):63-9. PubMed ID: 12673891 [TBL] [Abstract][Full Text] [Related]
18. Soluble and cellular markers of immune activation in patients with systemic sclerosis. Degiannis D; Seibold JR; Czarnecki M; Raskova J; Raska K Clin Immunol Immunopathol; 1990 Aug; 56(2):259-70. PubMed ID: 2116249 [TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 and soluble interleukin-2-receptor in psoriatic arthritis: correlations with clinical and laboratory parameters. Spadaro A; Taccari E; Riccieri V; Sensi F; Sili Scavalli A; Zoppini A Clin Exp Rheumatol; 1996; 14(4):413-6. PubMed ID: 8871841 [TBL] [Abstract][Full Text] [Related]